GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tianjin Chase Sun Pharmaceutical Co Ltd (SZSE:300026) » Definitions » EBITDA Margin %

Tianjin Chase Sun Pharmaceutical Co (SZSE:300026) EBITDA Margin % : 6.30% (As of Mar. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Tianjin Chase Sun Pharmaceutical Co EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Tianjin Chase Sun Pharmaceutical Co's EBITDA for the three months ended in Mar. 2024 was ¥92 Mil. Tianjin Chase Sun Pharmaceutical Co's Revenue for the three months ended in Mar. 2024 was ¥1,463 Mil. Therefore, Tianjin Chase Sun Pharmaceutical Co's EBITDA margin for the quarter that ended in Mar. 2024 was 6.30%.


Tianjin Chase Sun Pharmaceutical Co EBITDA Margin % Historical Data

The historical data trend for Tianjin Chase Sun Pharmaceutical Co's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tianjin Chase Sun Pharmaceutical Co EBITDA Margin % Chart

Tianjin Chase Sun Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.02 13.93 15.20 16.43 16.61

Tianjin Chase Sun Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.94 11.93 13.25 2.37 6.30

Competitive Comparison of Tianjin Chase Sun Pharmaceutical Co's EBITDA Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Tianjin Chase Sun Pharmaceutical Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tianjin Chase Sun Pharmaceutical Co's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tianjin Chase Sun Pharmaceutical Co's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Tianjin Chase Sun Pharmaceutical Co's EBITDA Margin % falls into.



Tianjin Chase Sun Pharmaceutical Co EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Tianjin Chase Sun Pharmaceutical Co's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=1014.504/6108.855
=16.61 %

Tianjin Chase Sun Pharmaceutical Co's EBITDA Margin % for the quarter that ended in Mar. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=92.146/1463.378
=6.30 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tianjin Chase Sun Pharmaceutical Co  (SZSE:300026) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Tianjin Chase Sun Pharmaceutical Co EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Tianjin Chase Sun Pharmaceutical Co's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Tianjin Chase Sun Pharmaceutical Co (SZSE:300026) Business Description

Traded in Other Exchanges
N/A
Address
No. 20, Quanfa Road, Tianjin Wuqing Development Area, Tianjin, CHN, 301700
Tianjin Chase Sun Pharmaceutical Co Ltd is a high-tech medicine and health industry group. The company offers Chinese herb preparation products, medicinal granules, synthetic drugs, biotech drugs, medical apparatus, and Internet-based therapy.
Executives
Yao Xiao Qing Director
Chen Rui Qiang Executives
Li Chun Xu Executives
Lan Wu Jun Directors, Directors, and Executives
Zheng Dan Directors, executives
Zhang Kun Executives
Gao Guo Wei Executives
Shang Xiao Mei Securities Affairs Representative
Sun Zhang Hai Director
Wu Guang Ning Supervisors
Wang Long Executives
Liu Qiang Supervisors
Ceng Guo Zhuang Director
Su Bing Jun Directors, executives
Nie Wei Supervisors

Tianjin Chase Sun Pharmaceutical Co (SZSE:300026) Headlines

No Headlines